The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...
All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...
The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...
MarketBeat on MSN8d
Johnson & Johnson Earnings Transcript (NYSE:JNJ)Presentation Operator Good morning and welcome to Johnson and Johnson's fourth quarter 2024 earnings conference call. All ...
(RTTNews) - Johnson & Johnson (JNJ), Tuesday announced that the U.S. Food and Drug Administration has approved supplemental New Drug Application or sNDA for Spravato, a monotherapy for adults with ...
Johnson & Johnson announced the U.S. FDA approval of a supplemental New Drug Application for Spravato CIII nasal spray, making this ...
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...
-Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback